Sangamo Therapeutics Receives Delisting Warning from Nasdaq, Faces Critical Listing Review
Sangamo Therapeutics, a genomic medicine company focused on gene editing, has received a formal notice from Nasdaq indicating potential delisting due to failure to meet continued listing standards. The filing, submitted to the SEC on April 29, 2026, under Item 3.01 of Form 8-K, reveals that the company was notified it no longer satisfies the exchange's minimum bid price requirement or other applicable listing criteria. This notice represents a significant escalation in the regulatory pressure facing Sangamo, signaling that the company's shares could be suspended or removed from the Nasdaq exchange if corrective actions are not implemented within the prescribed timeframe.
The biotech firm, which has historically operated in the competitive landscape of zinc finger protein gene editing technologies, appears to have fallen below the $1.00 minimum bid price per share threshold that Nasdaq mandates for continued listing on the Nasdaq Global Select Market. Nasdaq's listing rules provide companies with a specified period to regain compliance, typically through actions such as implementing a reverse stock split or demonstrating sustained market price recovery. The nature and timeline of any compliance plan Sangamo intends to pursue remains unclear from the disclosure. Company representatives have not yet publicly outlined specific remediation strategies in response to the delisting notice.
A delisting would carry substantial consequences for Sangamo Therapeutics, potentially restricting access to public capital markets and undermining investor confidence in the company. The loss of a national securities exchange listing could also accelerate existing financial pressures on a company that has faced ongoing challenges in advancing its clinical pipeline and securing sufficient funding. Market observers will likely monitor whether Sangamo pursues a reverse split, seeks alternative listing venues, or attempts to negotiate an extension with Nasdaq regulators. The company's next moves will determine whether it can retain its public market status or transition to over-the-counter trading.